Tumor cells expressing PD-L1 evade T cell antitumor response involving anergy or apoptosis of the effector T cells because the binding of PD-1 with PD-L1 results in apoptosis inhibition, T-lymphocyte tolerance, and increased tumor cell survival [45]. The gene discussed is PDCD1; the disease is neoplasm.